Oruka Therapeutics, Inc. (ORKA) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
ORKA currently has 55.2M outstanding shares. with minimal authorized share overhang for future dilution. The company has significantly diluted shareholders by 2874.56% over the past 2 years, indicating aggressive capital raising. Recent corporate actions include 1 stock split (positive for accessibility) and 1 reverse split (concerning signal).
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 13, 2026 |
10-Q filing | 55.2M shares outstanding |
55M | 0 |
| Apr 02, 2026 |
S-3 filing: Oruka Therapeutics, Inc. may offer and sell up to an aggregate amount of $1,000,000,000 of any combination of common stock, preferred stock and depositary shares. |
46M | 0 |
| Mar 12, 2026 |
10-K filing | 45.6M shares outstanding |
46M | 0 |
| Nov 12, 2025 |
10-Q filing | 44.1M shares outstanding |
44M | 0 |
| Oct 14, 2025 |
S-3/A filing: The Selling Stockholders may sell all or a portion of the Resale Shares beneficially owned by them and offered hereby from time to time. |
37M | 0 |
| Oct 14, 2025 |
S-3/A filing: The company is offering shares of its common stock, with an aggregate offering price of up to $200,000,000, from time to time through TD Cowen, acting as its agent or principal. |
37M | 0 |
| Oct 03, 2025 |
S-3 filing: The filing is for a potential offering of common stock with an aggregate offering price of up to $200,000,000 through an at-the-market offering. |
37M | 0 |
| Sep 22, 2025 |
8-K filing: Oruka Therapeutics, Inc. completed a private placement on September 19, 2025, selling 10,933,405 shares of common stock at $15.00 per share and pre-funded warrants to purchase 1,066,666 shares at $14.999 per warrant, resulting in gross proceeds of approximately $180 million. ($164.02M proceeds) |
48M | 0 |
| May 14, 2025 |
10-Q filing | 37.4M shares outstanding |
37M | 0 |
| Mar 06, 2025 |
POS AM filing: This is a post-effective amendment to a registration statement for the resale of common stock by selling stockholders, including shares from a private placement, conversion of preferred stock, and exercise of pre-funded warrants. |
37M | 0 |
| Mar 06, 2025 |
10-K filing | 37.4M shares outstanding |
37M | 0 |
| Nov 14, 2024 |
S-1 filing: This S-1 filing registers for resale 5,600,000 common shares, 2,439,000 common shares issuable upon conversion of Series A preferred stock, and 680,000 common shares issuable upon exercise of pre-funded warrants, all previously sold in a private placement. |
35M | 0 |
| Nov 13, 2024 |
10-Q filing | 35.0M shares outstanding |
35M | 0 |
| Sep 13, 2024 |
8-K filing: Oruka Therapeutics, Inc. entered into a Securities Purchase Agreement for a private placement with institutional and accredited investors, involving the sale of common shares, preferred shares, and pre-funded warrants for an aggregate purchase price of approximately $200.5 million, with the closing expected on September 13, 2024. |
1.2M | 2.3M |
| Aug 22, 2024 |
Stock Split
8-K filing: Stock split 1-for-12 | Outstanding: 14,506,879 → 1,208,423 |
1.2M | 2.3M |
| Aug 01, 2024 |
10-Q filing | 14.5M shares outstanding |
15M | 28M |
| Apr 25, 2024 |
10-Q filing | 14.5M shares outstanding |
15M | 28M |
| Feb 01, 2024 |
10-K filing | 14.4M shares outstanding |
14M | 28M |
| Oct 18, 2023 |
10-Q filing | 14.4M shares outstanding |
14M | 28M |
| Jul 21, 2023 |
10-Q filing | 14.4M shares outstanding |
14M | 28M |
| Apr 24, 2023 |
10-Q filing | 14.4M shares outstanding |
14M | 28M |
| Feb 24, 2023 |
10-K filing | 14.4M shares outstanding |
14M | 28M |
| Oct 28, 2022 |
10-Q filing | 14.4M shares outstanding |
14M | 28M |
| Aug 02, 2022 |
10-Q filing | 14.4M shares outstanding |
14M | 28M |
| May 02, 2022 |
10-Q filing | 14.4M shares outstanding |
14M | 28M |
| Mar 14, 2022 |
10-K filing | 14.4M shares outstanding |
14M | 28M |
| Nov 02, 2021 |
10-Q filing | 14.4M shares outstanding |
14M | 28M |
| Aug 04, 2021 |
10-Q filing | 14.4M shares outstanding |
14M | 28M |
| May 11, 2021 |
10-Q filing | 14.4M shares outstanding |
14M | 28M |
| Mar 22, 2021 |
S-3 filing: The filing is an S-3 registration statement to register an indeterminate amount of common stock, preferred stock, and debt securities, and warrants up to an aggregate initial offering price of $150,000,000. |
14M | 28M |
| Mar 18, 2021 |
10-K filing | 14.4M shares outstanding |
14M | 0 |
| Nov 02, 2020 |
10-Q filing | 9.3M shares outstanding |
9.3M | 0 |
| Aug 05, 2020 |
10-Q filing | 5.9M shares outstanding |
5.9M | 0 |
| Jul 14, 2020 |
8-K filing: ARCA biopharma, Inc. entered into Amendment No. 8 to its Capital on DemandTM Sales Agreement with JonesTrading Institutional Services LLC, increasing the maximum aggregate offering value of shares of the Company's common stock by $7,274,000, from $25,160,325 to $32,434,325. ($25.0M proceeds) |
1.6M | 3.6M |
| Jul 02, 2020 |
8-K filing: ARCA biopharma, Inc. entered into Amendment No. 7 to its Capital on DemandTM Sales Agreement with JonesTrading Institutional Services LLC, increasing the maximum aggregate offering value of shares of the Company's common stock by $7,636,600, from $17,523,725 to $25,160,325, and as of July 2, 2020, the Company had sold 1,087,858 shares of its common stock under the Sales Agreement for an aggregate offering price of approximately $17.4 million. ($17.4M proceeds) |
1.6M | 3.6M |
| May 07, 2020 |
S-3 filing: The company intends to offer and sell up to $75,000,000 of common stock, preferred stock, debt securities and/or warrants from time to time. |
1.6M | 3.6M |
| May 06, 2020 |
10-Q filing | 1.6M shares outstanding |
1.6M | 3.6M |
| Feb 26, 2020 |
S-1 filing: The company is offering up to $15,000,000 of shares of its Common Stock and warrants to purchase shares of common stock. |
1.6M | 3.6M |
| Feb 18, 2020 |
10-K filing | 1.6M shares outstanding |
1.6M | 0 |